Date: 2015-10-15
Type of information: Initiation of preclinical development
phase:
Announcement:
Company: Novartis (Switzerland) Vectura (UK)
Product: QVM149
Action
mechanism: long-acting beta2-agonist (LABA)/ long-acting muscarinic antagonist (LAMA)/corticosteroid. QVM149 is a fixed dose, once daily combination of the long-acting beta2-agonist (LABA) indacaterol, the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide and the inhaled corticosteroid (ICS) mometasone fuorate. Glycopyrronium bromide was licensed exclusively to Novartis in April 2005 by Vectura and its co-development partner Sosei.
Disease: asthma
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Country:
Trial
details:
Latest
news: * On June 18, 2015, Vectura confirms Novartis announced plans to develop a new inhaled dry powder triple therapy for patients with moderate to severe asthma uncontrolled on standard ICS/LABA medication. Novartis will present this information at an Investor Event \"Meet Novartis Management\" in Boston, USA. First regulatory filings of QVM149 are planned for 2018. Under the terms of the agreement with Novartis, Vectura is eligible to receive development, filing and approval milestones. In addition, Vectura will receive royalties on products sales in the event of a successful product launch.
